Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda
25 1월 2024 - 10:07PM
Dow Jones News
By Rob Curran
Lava Therapeutics shares surged after the biotech company said
one of its product candidates would be tested on prostate-cancer
patients in combination with Merck's blockbuster Keytruda drug.
The Dutch biopharmaceutical firm said the LAVA-1207 drug will be
tested in combination with Keytruda on patients with therapy
refractory metastatic castration-resistant prostate cancer, a
particularly severe form of the disease.
Like Keytruda, Lava's suite of Gammabody drugs use an
immunotherapy approach to target cancer cells. Merck will supply
the Keytruda doses for patients in Lava's ongoing early-stage Phase
1/2a clinical trial of LAVA-1207, with the combination set to begin
in the first half of this year.
Shares of Lava rose 32% to $2.06.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 25, 2024 07:52 ET (12:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
LAVA Therapeutics NV (NASDAQ:LVTX)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 4월(4) 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
과거 데이터 주식 차트
부터 4월(4) 2023 으로 4월(4) 2024
